O câncer de mama constitui o segundo tipo de câncer mais frequente no mundo e o mais comum entre as mulheres, representando uma das principais causas de morte. O tamoxifeno é um fármaco antiestrogênico utilizado para o tratamento deste tipo de câncer desde 1971 e ainda é o mais utilizado nos casos de tumores mamários que expressam receptores de estrógeno. Apesar de apresentar resultados significativamente positivos, seu efeito antiestrogênico não se restringe apenas ao sítio tumoral causando, com isso, efeitos colaterais graves que podem deixar sequelas. A proposta deste trabalho foi desenvolver sistemas de liberação nanoparticulados à base de PLA e PLA-PEG para veiculação do tamoxifeno, como uma estratégia para o potencial aumento da segurança e da eficácia deste fármaco através de um possível direcionamento passivo ao sítio de ação, devido à permeabilidade vascular aumentada destas regiões tumorais. As nanopartículas foram preparadas pela técnica de nanoprecipitação e apresentaram diâmetro médio inferior a 200 nm para a maioria das formulações. Foram avaliados três estabilizantes, o poloxamer 407, o poloxamer 188 e o polissorbato 80, este último proporcionou maior eficiência de encapsulação, 86,7% e 100%, nas nanopartículas de PLA e PLA-PEG, respectivamente. Quanto à composição das nanopartículas de PLA-PEG, o polímero utilizado inicialmente (PLA(1000)-PEG(750)) apresentou distribuição de tamanho heterogênea, perfil multimodal e alto índice de polidispersividade. Assim, este polímero foi substituído pelo PLA(5000)-PEG(1000), que apresentou distribuição de tamanho uniforme, perfil monomodal e baixo índice de polidispersividade. A caracterização por microscopia eletrônica de varredura comprovou a homogeneidade no tamanho de partícula, mostrando seu formato esférico. As análises de espectrofotometria no infravermelho e calorimetria diferencial exploratória sugeriram que não ocorreu nenhum tipo de interação ou reação entre o fármaco e os demais componentes das formulações. Dois métodos analíticos para a determinação do tamoxifeno foram validados com sucesso por CLAE e espectroscopia UV-vis. O perfil de liberação in vitro do tamoxifeno a partir das nanopartículas de PLA apresentou característica sustentada e alcançou 50% em 180 h, tendo sido totalmente liberado após 288 h. Já as nanopartículas de PLA(5000)-PEG(1000) liberaram apenas 16,9% do fármaco após 216 h. A liberação do fármaco a partir das nanopartículas foi muito mais lenta comparada ao tamoxifeno não encapsulado, evidenciando a vantagem da incorporação do fármaco em nanopartículas compostas por PLA e PLA-PEG. No estudo do perfil de concentração plasmática em ratas Wistar, não foi possível detectar o fármaco e seu principal metabólito pelo método por CLAE desenvolvido, sugerindo que os sistemas nanoparticulados tenham extravasado rapidamente para os órgãos. / Breast cancer is the second most frequent type of cancer in the world and it is the most common among women, representing a major cause of death. Tamoxifen is an antiestrogen drug used in the treatment of this type of cancer since 1971 and it is the most employed drug in the treatment of breast cancer subtypes that expresses estrogen receptors. Despite presenting significantly positive results, its antiestrogen effect is not restricted to the tumour site, causing, as consequence, severe side effects. The purpose of this work was to develop nanostructured drug delivery systems based on PLA and PLA-PEG loaded with tamoxifen, as a strategy to potentially increase the safety and efficacy of this drug through a possible passive accumulation the site of action, due to the enhanced vascular permeability of tumour sites. Nanoparticles were prepared by the nanoprecipitation technique and presented average diameter smaller than 200 nm for the majority of the formulations. Three stabilizing adjuvants were analysed, poloxamer 407, poloxamer 188 and polysorbate 80 and the last one yielded the highest encapsulation efficiency, 86.7% and 100%, for the PLA and PLA-PEG nanoparticles, respectively. Regarding the PLA-PEG nanoparticles composition, the first polymer employed was (PLA(1000)-PEG(750)), which presented heterogeneous particle size distribution, multimodal profile and high polydispersity index. So, it was replaced by PLA(5000)-PEG(1000), which exhibited uniform particle size distribution, monomodal profile and low polydispersity index. The characterization by scanning electron microscopy confirmed the homogeneity of particles size, evidencing their spherical shape. Infrared spectrophotometry and differential scanning calorimetry analysis suggested that any interaction or reaction had occurred between the drug and the other components of the formulations. Two analytical methods for tamoxifen quantification were successfully validated by HPLC and UV-vis spectroscopy. In vitro tamoxifen release profile from PLA nanoparticles presented sustained release and reached 50% in 180 h, being completely released after 288 h, whereas PLA(5000)-PEG(1000) nanoparticles released only 16.9% of tamoxifen after 216 h. Drug release from nanoparticles was much slower compared to the non-encapsulated tamoxifen, showing the advantage of nanoparticles composed of PLA and PLA-PEG. In the plasmatic concentration profile study carried out in Wistar rats, it was not possible to detect tamoxifen or its main metabolite by the HPLC method, suggesting that nanoparticles quickly extravased to organs.

O câncer de mama constitui o segundo tipo de câncer mais frequente no mundo e o mais comum entre as mulheres, representando uma das principais causas de morte. O tamoxifeno é um fármaco antiestrogênico utilizado para o tratamento deste tipo de câncer desde 1971 e ainda é o mais utilizado nos casos de tumores mamários que expressam receptores de estrógeno. Apesar de apresentar resultados significativamente positivos, seu efeito antiestrogênico não se restringe apenas ao sítio tumoral causando, com isso, efeitos colaterais graves que podem deixar sequelas. A proposta deste trabalho foi desenvolver sistemas de liberação nanoparticulados à base de PLA e PLA-PEG para veiculação do tamoxifeno, como uma estratégia para o potencial aumento da segurança e da eficácia deste fármaco através de um possível direcionamento passivo ao sítio de ação, devido à permeabilidade vascular aumentada destas regiões tumorais. As nanopartículas foram preparadas pela técnica de nanoprecipitação e apresentaram diâmetro médio inferior a 200 nm para a maioria das formulações. Foram avaliados três estabilizantes, o poloxamer 407, o poloxamer 188 e o polissorbato 80, este último proporcionou maior eficiência de encapsulação, 86,7% e 100%, nas nanopartículas de PLA e PLA-PEG, respectivamente. Quanto à composição das nanopartículas de PLA-PEG, o polímero utilizado inicialmente (PLA(1000)-PEG(750)) apresentou distribuição de tamanho heterogênea, perfil multimodal e alto índice de polidispersividade. Assim, este polímero foi substituído pelo PLA(5000)-PEG(1000), que apresentou distribuição de tamanho uniforme, perfil monomodal e baixo índice de polidispersividade. A caracterização por microscopia eletrônica de varredura comprovou a homogeneidade no tamanho de partícula, mostrando seu formato esférico. As análises de espectrofotometria no infravermelho e calorimetria diferencial exploratória sugeriram que não ocorreu nenhum tipo de interação ou reação entre o fármaco e os demais componentes das formulações. Dois métodos analíticos para a determinação do tamoxifeno foram validados com sucesso por CLAE e espectroscopia UV-vis. O perfil de liberação in vitro do tamoxifeno a partir das nanopartículas de PLA apresentou característica sustentada e alcançou 50% em 180 h, tendo sido totalmente liberado após 288 h. Já as nanopartículas de PLA(5000)-PEG(1000) liberaram apenas 16,9% do fármaco após 216 h. A liberação do fármaco a partir das nanopartículas foi muito mais lenta comparada ao tamoxifeno não encapsulado, evidenciando a vantagem da incorporação do fármaco em nanopartículas compostas por PLA e PLA-PEG. No estudo do perfil de concentração plasmática em ratas Wistar, não foi possível detectar o fármaco e seu principal metabólito pelo método por CLAE desenvolvido, sugerindo que os sistemas nanoparticulados tenham extravasado rapidamente para os órgãos. / Breast cancer is the second most frequent type of cancer in the world and it is the most common among women, representing a major cause of death. Tamoxifen is an antiestrogen drug used in the treatment of this type of cancer since 1971 and it is the most employed drug in the treatment of breast cancer subtypes that expresses estrogen receptors. Despite presenting significantly positive results, its antiestrogen effect is not restricted to the tumour site, causing, as consequence, severe side effects. The purpose of this work was to develop nanostructured drug delivery systems based on PLA and PLA-PEG loaded with tamoxifen, as a strategy to potentially increase the safety and efficacy of this drug through a possible passive accumulation the site of action, due to the enhanced vascular permeability of tumour sites. Nanoparticles were prepared by the nanoprecipitation technique and presented average diameter smaller than 200 nm for the majority of the formulations. Three stabilizing adjuvants were analysed, poloxamer 407, poloxamer 188 and polysorbate 80 and the last one yielded the highest encapsulation efficiency, 86.7% and 100%, for the PLA and PLA-PEG nanoparticles, respectively. Regarding the PLA-PEG nanoparticles composition, the first polymer employed was (PLA(1000)-PEG(750)), which presented heterogeneous particle size distribution, multimodal profile and high polydispersity index. So, it was replaced by PLA(5000)-PEG(1000), which exhibited uniform particle size distribution, monomodal profile and low polydispersity index. The characterization by scanning electron microscopy confirmed the homogeneity of particles size, evidencing their spherical shape. Infrared spectrophotometry and differential scanning calorimetry analysis suggested that any interaction or reaction had occurred between the drug and the other components of the formulations. Two analytical methods for tamoxifen quantification were successfully validated by HPLC and UV-vis spectroscopy. In vitro tamoxifen release profile from PLA nanoparticles presented sustained release and reached 50% in 180 h, being completely released after 288 h, whereas PLA(5000)-PEG(1000) nanoparticles released only 16.9% of tamoxifen after 216 h. Drug release from nanoparticles was much slower compared to the non-encapsulated tamoxifen, showing the advantage of nanoparticles composed of PLA and PLA-PEG. In the plasmatic concentration profile study carried out in Wistar rats, it was not possible to detect tamoxifen or its main metabolite by the HPLC method, suggesting that nanoparticles quickly extravased to organs.

Made available in DSpace on 2014-06-11T19:32:09Z (GMT). No. of bitstreams: 0 Previous issue date: 2007-04-04Bitstream added on 2014-06-13T20:23:05Z : No. of bitstreams: 1 mainardes_rm_dr_arafcf.pdf: 1864850 bytes, checksum: f49ab7e28e985faad2f32205305f0de3 (MD5) / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / Universidade Estadual Paulista (UNESP) / A zidovudina (AZT) é um fármaco amplamente usado no tratamento da síndrome da imunodeficiência adquirida. O AZT apresenta baixa biodisponibilidade oral pois sofre rápido e extenso metabolismo de primeira passagem hepática, além de curto t1/2. Sendo assim, altas e freqüentes doses são requeridas para se manter concentrações plasmáticas efetivas e, dessa maneira, apresenta graves efeitos colaterais, dose-dependentes, que limitam o seu uso em determinados tipos de pacientes. As nanopartículas são eficientes sistemas poliméricos que contribuem para a redução da toxicidade de fármacos, pois são capazes de liberá-los de maneira prolongada, proporcionando maior tempo de contato do fármaco com o plasma e tecidos. A via de administração intranasal é uma rota interessante, quando se deseja evitar o metabolismo de primeira passagem e, também, pode oferecer um ótimo perfil de absorção para nanopartículas. Neste trabalho, estudouse a incorporação de AZT em nanopartículas de PLA e de blendas de PLA-PEG com diferentes razões molares. A caracterização físico-química demonstrou que a presença do PEG influenciou a forma, o diâmetro médio, a eficiência de encapsulação, assim como o potencial de superfície das partículas. O diâmetro médio e a eficiência de encapsulação das nanopartículas aumentaram com o aumento crescente da razão molar de PEG na blenda. A forma geral e a apresentação das partículas variaram em função da concentração de PEG, sendo que os melhores resultados foram obtidos com as menores razões molares deste na blenda. Os experimentos de liberação in vitro mostraram que a liberação do AZT a partir das nanopartículas foi mais lenta em relação ao AZT em solução. A presença do PEG nas nanopartículas alterou o perfil de liberação do AZT, tornando... / Zidovudine (AZT) is a drug widely used in the treatment of acquired immunodeficiency syndrome. AZT shows low bioavailability because it suffers fast and extensive by pass hepatic metabolism, besides of low t1/2. High and frequent doses are requested to achieve effective plasmatic concentrations, and thus, it shows serious and dosedependents side effects that limit its use in certain kind of patients. Nanoparticles are efficient polymeric systems that contributes to reduce the drug toxicity, because maintain prolonged drug release, making longer the contact between drug and plasma/tissues. The intranasal way is a very interesting route to avoid the by pass metabolism, and also offers a great absorption profile to nanoparticles. In the present work, the AZT encapsulation in PLA e PLA-PEG blends nanoparticles was studied. The physico-chemical characterization showed that the presence of PEG influences the nanoparticles shape, mean diameter, encapsulation efficiency and superficial charge. The mean diameter and encapsulation efficiency increase with increasing PEG proportion in the blend. The nanoparticles shape varied in function of PEG concentration, the better results being obtained with the lowest PEG concentration. In vitro experiments showed that AZT release from nanoparticles was slower than that of AZT solution. The presence of PEG in nanoparticles altered the AZT release profile, making it faster than that from PLA nanoparticles. The ex vivo phagocytosis experiments demonstrated that PLA-PEG blends nanoparticles were more efficient in avoiding the activation of phagocytic cells. The intranasal bioavailability in rats shows that blend PLA-PEG nanoparticles demonstrated longer plasmatic circulating times than that those make of PLA alone. These results demonstrate that PLA and PLA-PEG blends nanoparticles can be used as an efficient intranasal drug delivery system.

Η Πακλιταξέλη (PTX) αποτελεί ένα ευρέως διαδεδομένο αντινεοπλασματικό φάρμακο και ενδείκνυται σε μεταστατικό καρκίνο του μαστού, καρκίνο ωοθηκών, μη μικροκυτταρικό καρκίνο του πνεύμονα και σε σάρκωμα Kaposi ασθενών με AIDS. Παρ’ όλα αυτά, η σημαντική τοξικότητα που εμφανίζει (μυελοκαταστολή, νευροτοξικότητα, αντιδράσεις υπερευαισθησίας), υπογραμμίζει την αναγκαιότητα για μορφοποίησή της σε Συστήματα Ελεγχόμενης Χορήγησης Φαρμάκων (DDS), με σκοπό τη μείωση των ανεπιθύμητων ενεργειών και την αύξηση της βιοδιαθεσιμότητας του φαρμάκου. Τα πολυμερικά μικκύλια έχουν μελετεθεί εκτενώς τα τελευταία χρόνια ως Συστήματα Ελεγχόμενης Χορήγησης Φαρμάκων. Η ενσωμάτωση υπερπαραμαγνητικών νανοκρυσταλλιτών οξειδίου του σιδήρου (SPIONs) στον πυρήνα των PTX-μικκυλίων, παρέχει τη δυνατότητα μαγνητικής στόχευσης του φαρμάκου στην επιθυμητή περιοχή δράσης, καθώς και τη θεραπεία του καρκίνου μέσω επαγωγής μαγνητικής υπερθερμίας, με την εφαρμογή εναλλασσόμενου μαγνητικού πεδίου. Επιπλεόν, η χρήση των SPIONs ως σκιαγραφικά μέσα (Τ2-contrast enhancement) στη μαγνητική τομογραφία πυρηνικού συντονισμού (MRI), εξασφαλίζει το πλεονέκτημα ταυτόχρονης διάγνωσης και θεραπείας (Theranostics), αποκαλύπτοντας την πολυλειτουργικότητα των συστημάτων αυτών. Οι συγκεκριμένοι νανοφορείς, έχοντας μικρό μέγεθος (100-200nm), θεωρούνται κατάλληλοι για να αποφύγουν την οψωνινοποίηση απο τις λιποπρωτεϊνες του αίματος, την επίθεση απο τα φαγοκύτταρα του Δικτυοενδοθηλιακού συστήματος (RES) καθώς και την ταχεία νεφρική κάθαρση, με αποτέλεσμα την παρατεταμένη κυκλοφορία τους στο αίμα (stealth systems) και την εκλεκτική πρόσληψη τους απο τους συμπαγείς καρκινικούς όγκους, μέσω του φαινομένου της ενισχυμένης διαπερατότητας και κατακράτησης (EPR effect). Οι ιδιότητες αυτές, καθιστούν τα συγκεκριμένα συστήματα πολύτιμα εργαλεία στον τομέα της νανοϊατρικής. Η παρούσα μεταπτυχιακή διατριβή πραγματεύεται τη σύνθεση υδρόφοβων SPIONs μέσω της τεχνικής της θερμικής αποικοδόμησης. Μελετήθηκαν οι συνθετικές παράμετροι (πρόδρομη ένωση, ποσότητα ελαϊκού οξέος, θερμοκρασία και διάρκεια αντίδρασης, ρυθμός αύξησης της θερμοκρασίας κ.α) που επηρεάζουν το μέγεθος, το σχήμα και τη διασπορά του μεγέθους των σχηματιζομένων νανοκρυσταλλιτών (5-13nm, σ: 10-20%), καθώς διαδραματίζουν σημαντικό ρόλο στη μαγνητική συμπεριφορά των υβριδικών νανονοφορέων. Στη συνέχεια, πραγματοποιήθηκε σύνθεση υβριδικών νανοφορέων με εγκλωβισμό των SPIONs σε πολυμερικά μικκύλια. Η παρασκευή των υπερπαραμαγνητικών μικκυλίων επιτελέστηκε με την τεχνικη solvent diffusion and evaporation (nanoprecipitation), με χρήση του αμφίφιλου συμπολυμερούς πολυ(γαλακτικό οξύ)-πολυ(αιθυλενογλυκόλη) (PLA-PEG). Στον υδρόφοβο πυρήνα των μικκυλίων (PLA) δεσμεύονται υδρόφοβες ενώσεις (PTX, SPIONs), ενώ το υδρόφιλο κέλυφος (PEG) προσδίδει κολλοειδή σταθερότητα σε υδατικά μέσα (δομή πυρήνα-κελύφους). Διερευνήθηκαν διάφορες συνθετικές παράμετροι (μοριακό βάρος συμπολυμερούς, ποσότητα SPIONs, ρυθμός προσθήκης οργανικής φάσης κ.α) και προσδιορίστηκαν οι βέλτιστες συνθήκες για την παρασκευή υπερπαραμαγνητικών μικκυλίων μεγέθους <200nm, με αξιοσημείωτη κολλοειδή σταθερότητα (μέχρι και έξι μήνες), σε συνθήκες παρόμοιες με αυτές του ανθρώπινου πλάσματος (pH: 7.4, ιοντική ισχύς: 0.15Μ). Στο επόμενο στάδιο της παρούσας εργασίας, μελετήθηκαν οι παράγοντες που επηρεάζουν τη φόρτωση-ενκαψυλίωση της PTX και των SPIONs στα πολυμερικά μικκύλια (ποσότητα PTX, ποσότητα και μέγεθος SPIONs, μοριακό βάρος PLA-PEG, ρυθμός προσθήκης οργανικής φάσης κ.α), σε φυσιολογικές συνθήκες (pH:7.4, ιοντική ισχύς: 0.15Μ). Αναπτύχθηκε πρωτόκολλο μέσω του οποίου έγινε κατορθωτός ο διαχωρισμός των μαγνητικών νανοφορέων απο τους μη μαγνητικούς, καθώς και ο υπολογισμός της φόρτωσης-ενκαψυλίωσης PTX και SPIONs ξεχωριστά, τόσο στους μαγνητικούς και μη μαγνητικούς νανοφορείς, όσο και στο μέιγμα αυτών. Οι συγκεκριμένοι νανοφορείς χαρακτηρίζονται απο εξαιρετικά υψηλή απόδοση ενκαψυλίωσης φαρμάκου (93 %wt.) και φόρτωση φαρμάκου που ανέρχεται στο 4.8 %wt. Oι αμιγώς μαγνητικοί νανοφορείς επιδεικνύουν υψηλή απόδοση ενκαψυλίωσης νανοκρυσταλλιτών (70 %wt.), ενώ η φόρτωση σε φάρμακο και SPIONs ανέρχεται σε 5.2 και 20 %wt. αντίστοιχα. Σε αμφότερες τις περιπτώσεις οι νανοφορείς, μεγέθους (υδροδυναμική διάμετρος) 170nm, χαρακτηρίζονται απο ικανοποιητική μαγνητική συμπεριφορά. Εξετάστηκε η επίδραση του μεγέθους των νανοκρυσταλλιτών στη μαγνητική συμπεριφορά των νανοφορέων. Οι αμιγώς μαγνητικοί νανοφορείς με μεγαλύτερο μέγεθος SPIONs παρουσιάζουν καλύτερη μαγνητική συμπεριφορά. Τέλος, πραγματοποιήθηκαν μελέτες αποδέσμευσης του φαρμάκου σε PBS (0.14Μ, pH:7.4) στους 37oC και διερευνήθηκε η επίδραση της εφαρμογής εναλλασσόμενου μαγνητικού πεδίου στην αποδέσμευση της PTX απο τους μαγνητικούς νανοφορείς (Triggered Drug Release). Σε κάθε περίπτωση, παρατηρήθηκε ελεγχόμενη αποδέσμευση του φαρμάκου για 24 ώρες, σε συνθήκες που προσομοιάζουν με αυτές του πλάσματος. Ο φυσικοχημικός χαρακτηρισμός των νανοφορέων πραγματοποιήθηκε με HPLC, DLS, TGA, TEM και μαγνητοφόρηση. / Paclitaxel (PTX) is one of the most successful anticancer drugs against a broad range of solid tumors, such as metastatic breast cancer, ovarian cancer, non-small-cell lung cancer and AIDS-related Kaposi sarcoma. However, the serious systematic side effects of PTX (myelosuppression, neurotoxicity, hypersensitivity) underline the need for formulation of PTX in Drug Delivery Systems (DDS), in order to reduce the side effects and increase the bioavailability of the drug. Among DDS, polymeric micelles have drawn much attention due to their great flexibility in tuning drug solubility, micelle size, targeted drug delivery and stability. Incorporation of Superparamagnetic Iron Oxide Nanocrystals (SPIONs) inside the core of drug-loaded polymeric micelles, imparts to the final Drug Delivery System the prospect of physical (magnetic) targeting, intrinsic therapeutic function (hyperthermia-based cancer therapy under alternating external magnetic field), T2-based contrast enhancement in magnetic resonance imaging (MRI) and remotely triggered drug release. These core-shell polymeric micelles having small size (100-200nm), are considered appropriate for avoiding both opsonization, macrophages attack by ReticuloEndothelial System (RES) and rapid renal clearance, thus allowing micelles to be taken up preferably by solid tumors through Enhanced Permeability and Retention (EPR) effect. Therefore, such nanoassemblies encode high potential in nanomedicine, due to their dual nature (Therapeutic+Diagnostic = Theranostics). In particular, we have studied the synthesis of organophilic SPIONs through thermal decomposition. The synthetic parameters (precursor, precursor:oleic acid ratio, reaction temperature and duration, heat rate, etc.) affecting the size, shape and size distribution of the nanocrystals have also been examined thoroughly, since they play a key-role concerning the magnetic behavior of the final hybrid. Nanosized SPIONs with narrow size distribution were synthesized (5-13nm, σ: 10-20%). The preparation of poly(lactic acid)-block-poly(ethyleneglycol) (PLA-PEG) micelles encapsulating hydrophobic SPIONs, by varying the molecular weight of the polymers, the amount of SPIONs and the addition rate during micelle assembly, has also been investigated. The core-shell superparamagnetic micelles were prepared through solvent diffusion and evaporation technique (nanoprecipitation). PTX and SPIONs are being incorporated into the micelle’s hydrophobic core (PLA) through hydrophobic interactions, whereas the hydrophilic shell (PEG) stabilizes the micelles in aqueous dispersions, optimizing their colloidal stability and providing prolonged circulating time. The optimum parameters were determined, conferring to the micelles (Hydrodynamic Diameter < 200nm) high colloidal stability (up to six months) at biorelevant conditions (pH:7.4, ionic strenght: 0.15M). The next phase of the present master thesis focused on studying the factors (amount of PTX and SPIONs, molecular weight of PLA-PEG, addition rate, etc.) affecting the Loading of PTX and SPIONs into the polymeric micelles and how they can be fine-tuned towards high drug loading, while retaining their size at a scale where long circulation would not be precluded. Through protocol establishment, we have managed to separate the magnetic and non magnetic micelles, and to determine individually the loading of PTX and SPIONs for magnetic, non magnetic micelles, as well as for the mixture of them. The micelles’ mixture exhibits very high Drug Encapsulation Efficiency (93 %wt.) and 4.8 %wt. Drug Loading (D.L). Magnetic nanocarriers display high Magnetic Encapsulation Efficiency (70 %wt.), with D.L and Magnetic Loading of 5.2 and 20 %wt. respectively, In both cases, micelles demonstrate adequate magnetic behavior and small sizes (hydrodynamic diameter: 170nm), under conditions which simulate with human plasma (pH:7.4, ionic strenght: 0.15M). The effect of SPIONs’ size on the magnetic behavior of hybrid colloids, was also examined. Magnetic nanocarriers encapsulating SPIONs of greater size exhibit better magnetic behavior. Finally, we have conducted Drug release studies in PBS (0.14M, pH:7.4) at 37oC. The effect of SPIONs presence on the release profile of PTX, including triggered drug-release by application of AC magnetic field, has also been investigated. PTX-magnetic micelles exhibit Controlled Drug release for 24 hours. Several techniques have been used for the characterization of such nanoassemblies, like: HPLC, DLS, TGA, TEM, XRD, Magnetophoresis and Triggered Drug release by application of AC magnetic field.